Can-Fite BioPharma (NYSE:CANF) Earns Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Can-Fite BioPharma (NYSE:CANF) in a report released on Tuesday morning,Benzinga reports. They currently have a $10.00 target price on the stock.

Separately, StockNews.com assumed coverage on shares of Can-Fite BioPharma in a report on Saturday, March 15th. They issued a “sell” rating on the stock.

Can-Fite BioPharma Price Performance

NYSE:CANF opened at $1.51 on Tuesday. Can-Fite BioPharma has a one year low of $1.29 and a one year high of $4.69. The company has a market cap of $5.35 million, a P/E ratio of -0.84 and a beta of 1.12. The firm’s fifty day moving average price is $1.59 and its two-hundred day moving average price is $1.87.

Institutional Investors Weigh In On Can-Fite BioPharma

An institutional investor recently bought a new position in Can-Fite BioPharma stock. BNP Paribas Financial Markets acquired a new position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned approximately 0.71% of Can-Fite BioPharma as of its most recent SEC filing. 21.00% of the stock is owned by institutional investors.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.